The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-16 and is reviewed periodically as new material appears.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
In 1996 Merck paid $1.8 million for polluting the air. New machines were installed to reduce smog emissions by 680,000 lb (310,000 kg) a year. In November 1993, Merck & Co. acquired Medco Containment Services for $6 billion. Merck & Co. spun Medco off ten years later. Merck's supply chain reduction programme has been referred to as an example of successful change. Merck reduced its number of global suppliers from 40,000 to less than 10,000 during the period from 1992 to 1997.
=== Aromatase inhibitors === Aromatase inhibitors are an important class of drugs used for the treatment of breast cancer in postmenopausal women. At menopause, estrogen production in the ovaries ceases, but other tissues continue to produce estrogen through the action of the enzyme aromatase on androgens produced by the adrenal glands. When the action of aromatase is blocked, estrogen levels in post-menopausal women can drop to extremely low levels, causing growth arrest and/or apoptosis of hormone-responsive cancer cells.
Isotopes are nuclides with the same number of protons but differing numbers of neutrons; that is, they have the same atomic number and are therefore the same chemical element. Isotopes neighbor each other vertically. Examples include carbon-12, carbon-13, and carbon-14 in the table above. Isotones are nuclides with the same number of neutrons but differing numbers of protons. Isotones neighbor each other horizontally. Examples include carbon-14, nitrogen-15, and oxygen-16 in the table above. Isobars are nuclides with the same number of nucleons (i.e. mass number) but different numbers of protons and neutrons. Isobars neighbor each other diagonally from lower-left to upper-right. Examples include carbon-14, nitrogen-14, and oxygen-14 in the table above. Isodiaphers are nuclides with the same difference between their numbers of neutrons and protons (N − Z). Like isobars, they follow diagonal lines, but at right angles to the isobar lines (from upper-left to lower-right). Examples include boron-10, carbon-12, and nitrogen-14 (as N − Z = 0 for each pair), or boron-12, carbon-14, and nitrogen-16 (as N − Z = 2 for each pair). Beyond the neutron drip line along the lower left, nuclides decay by neutron emission. Beyond the proton drip line along the upper right, nuclides decay by proton emission. Drip lines have only been established for some elements. The island of stability is a hypothetical region in the top right cluster of nuclides that contains isotopes far more stable than other transuranic elements.
Sources: en.wikipedia.org
== House of Este == In 1452 Holy Roman Emperor Frederick III offered the duchy to Borso d'Este, whose family had ruled the city of Modena and nearby Reggio Emilia for centuries. Borso in 1450 had also succeeded his brother as margrave in the adjacent Papal Duchy of Ferrara, where he received the ducal title in 1471. The Este lands on the southern border of the Holy Roman Empire with the Papal States formed a stabilizing buffer state in the interest of both.
=== Dextran conjugate nanoparticles === Dextran conjugates are also utilized in nanoparticle drug delivery system formulations. Nanoparticles composted of dextran and stearic acid with a polyethylene glycol (PEG) coating can be loaded with antiviral drugs and be effectively internalized by cells. This nanosystem has the advantages of providing protection against immune responses and providing stability to the encapsulated drug. This technology has applications in the treatment of HIV and AIDS. Dextran can be grafted with folic acid to develop doxorubicin-loaded nanoparticles. Dextran-folic acid nanoparticles effectively target tumors, reduce off-site toxicity, and prolong blood circulation. Dextran-spermine nanoparticles loaded with doxorubicin can achieve targeted and sustained drug release in tumors.
In August, the Federal Police (PF) launched Operations Carbono Oculto, Quasar and Tank against a multibillion-real scheme of fraud in the fuel sector and money laundering, revealing that the First Capital Command (PCC) and companies in the financial market used fintechs and transactions via PIX to move and conceal large sums. According to the investigation, the absence of oversight, intensified by the disinformation that circulated on social media about the new Federal Revenue Service oversight rule that would be implemented at the beginning of the year but was revoked due to fake news, facilitated the criminal group's activity. Later, deputies requested the investigation of Nikolas over the video in which he criticized the new oversight of financial movements via Pix."These fake news were so strong that, despite all the effort of the Federal Revenue Service, we could not overcome these lies, because of the strength of those who boosted them. [...] And today's operations show who gained from these lies, from these fake news". — Robinson Barreirinhas, special secretary of the Federal Revenue Service.
Sources: en.wikipedia.org
229Th has a nuclear isomer, 229mTh, with an excitation energy of 8.355733554021(8) eV. This is by far the lowest of all nuclear isomers. Because this energy lies between thorium's first and second ionization energies of 6.3 and 11.5 eV, the decay rate of 229mTh is sensitive to the electronic environment of the nucleus. In neutral 229mTh, the isomer decays by internal conversion to 229Th+ within a few microseconds. However, the isomeric energy is not enough to remove a second electron, so internal conversion is impossible in 229mTh+ ions; they are forced to decay radiatively with a half-life 8.4 orders of magnitude longer, in excess of 1000 seconds. Embedded in ionic crystals, ionization is not quite 100%, so a small amount of internal conversion occurs, leading to a recently measured lifetime of ≈600 s, which can be extrapolated to a lifetime for isolated ions of 1740±50 s. Any photon emitted by nuclear decay is called a gamma ray, but this "gamma ray" has a frequency of 2020407384335±2 kHz (wavelength 148.3821828827(15) nm), in te far ultraviolet. This means it is possible to build a laser operating at this frequency, giving the only known opportunity for direct laser excitation of a nuclear state. This could have applications like a nuclear clock of very high accuracy or as a qubit for quantum computing. These applications were for a long time impeded by imprecise measurements of the isomeric energy, as laser excitation's exquisite precision makes it difficult to use to search a wide frequency range.
Gosogliptin (INN; trade name Saterex) is a drug for the treatment of type II diabetes. It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors (also called gliptins). It was discovered and developed through Phase 1 and Phase 2 by Pfizer. The crystal structure of DPP-4 in complex with gosogliptin is available. Its metabolism, excretion and pharmacokinetics in rat, dog and human have been described. A cost efficient route has been published. Other studies including Phase 3 studies were conducted in Russia. It is approved for use in Russia.
The New York Times checked the logs of MagtiCom cellular network and verified that the calls were indeed made between the Roki Tunnel and Tskhinvali at the indicated timestamps. Russian Defense Ministry official General Nikolai Uvarov claimed that Russia was not expecting a Georgian attack and earlier on 7 August Russian peacekeeping forces in South Ossetia was supplied with fuel and products; however, he asserted he didn't know anything about Colonel Kazachenko. Georgia called into question this Russian assertion. Instead, Georgia argued that movements of the Russian peacekeeping battalion could take place only during daytime. The rotation required at least a month of advance warning according to a mutual agreement of 2004. According to Uvarov, the first Russian combat unit (the 135th Regiment) was ordered after the Georgian attack to pass through the Roki Tunnel around dawn on 8 August and they entered South Ossetia by 14:30 on August 8; however, the Russian battalion managed to arrive in Tskhinvali only the next evening. Georgia instead asserted that first Georgian encounter with the Russian troops took place before the dawn of August 8.
A 2025 review highlights relevant candidates in the current antibiotic development pipeline and discusses alternative strategies, including phage therapy and immunotherapeutics, for the treatment of multidrug-resistant enterococci.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.